Research and Markets: Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/bpn5lf/critical_care) has announced the addition of the "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market" report to their offering.

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019

This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

This report provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutic Landscape

  • Albumin Products
  • Anti-Thrombin Concentrates
  • Factor XIII Concentrates
  • Fibrinogen Concentrates
  • Prothrombin Complex Concentrates

4 Pipeline for Critical Care Market

  • Overview of Pipeline
  • Promising Pipeline Candidates

5 Critical Care Market Forecast to 2020

  • Geographical Markets
  • Drivers and Barriers

6 Deals and Strategic Consolidations

  • Octapharma Enters Into an Agreement with Pfizer
  • Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis
  • Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Korea-based Bio-pharmaceutical Joint Venture
  • Bain Capital Acquires 80% Stake in Plasma Resources UK
  • Biomat Acquires Three Plasma Donation Centers from Cangene
  • BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact
  • Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
  • Shire Enters into Licensing Agreement with Sangamo BioSciences
  • Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma

7 Appendix

For more information visit http://www.researchandmarkets.com/research/bpn5lf/critical_care

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals